High dose of erythropoietin in management of interferon/ribavirin induced anemia.
Accumulating evidence now supports the use of recombinant human erythropoietin (rHuEPO) to manage anemia in PEG-IFN/RBV treated patients, with the objective of maintaining the RBV dose, but currently no official guidelines exist. Actually, rHuEPO exact utilizable dose in PEG-IFN/RBV treated patients is not known. We describe the case of a patient with severe ribavirin-induced anemia.
Ucciferri
Claudio
C
Clinic of Infectious Diseases, Department of Medicine and Aging University "G d'Annunzio" Chieti-Pescara, Italy.
Falasca
Katia
K
Mancino
Paola
P
De Tullio
Domenico
D
Pizzigallo
Eligio
E
Vecchiet
Jacopo
J
D000410:Alanine Transaminase / Q000097:blood; D000740:Anemia / Q000188:drug therapy*; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D000998:Antiviral Agents; D006454:Hemoglobins; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D012254:Ribavirin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase